New recommendations prioritise multiparametric MRI, safer transperineal biopsy, and earlier escalation for high-risk prostate-specific antigen relapse.

Can PSA derivatives reduce unnecessary prostate MRI after negative biopsy? Learn how simple markers may guide imaging ...

PSA density (PSAD) predicts pathologic upstaging following radical prostatectomy (RP) for prostate cancer, a study found. The finding suggests that PSAD may be an additional parameter that clinicians ...

The REIMAGINE study, published today in BMJ Oncology, is the first study to use MRI scans with prostate specific antigen (PSA) density to assess the need for further standard NHS tests. Of the 29 ...

Researchers recommend lowering it to 0.3-0.5 ng/mL per year when PSA level is below 4 ng/mL. ORLANDO—New findings presented here suggest clinicians should use a lower PSA velocity (PSAV) to recommend ...

The lexicon of PET/CT reports in prostate patients: Evaluating confidence. This is an ASCO Meeting Abstract from the 2022 ASCO Genitourinary Cancers Symposium. This abstract does not include a full ...

Using MRI scans in screening for prostate cancer could detect tumours missed by prostate-specific antigen (PSA) blood testing alone, according to a major new study from University College London (UCL) ...

MRI of the prostate, combined with a blood test, can help determine if a prostate lesion is clinically significant cancer, new research suggests. A new meta-analysis by investigators from Brigham and ...

Using MRI as a screening test alongside PSA density allowed detection of cancers that would have been missed by the blood test alone, according to new research. The REIMAGINE study, published today in ...